A rare case of splenic diffuse red pulp small B-cell lymphoma (SDRPL): a review of the literature on primary splenic lymphoma with hairy cells

TO THE EDITOR: Lymphomas with villous morphology are uncommon, and the rarest type is the splenic diffuse red pulp small B-cell lymphoma (SDRPL). Few SDRPL cases have been reported in the literature. There is considerable overlap with lymphomas that display villous lymphocytes in blood and splenomegaly, such as the rare variant hairy-cell leukemia, and splenic marginal zone lymphoma. Nonetheless, recent studies have produced clear, differentiating features regarding clinical, morphological, and immunophenotypical data. We highlight the case of a middle-aged male patient with massive splenomegaly and villous lymphocytes, diagnosed with SDRPL based on splenic histology and a characteristic immunoprofile. Diagnosis of SDRPL rests mainly on the exclusion of other lymphomas and on a correlation of bone marrow and spleen histology, and immunophenotyping. Our experience provides further support in considering this enigmatic lymphoma as a distinct entity within the WHO classification of lymphoid neoplasms.
Introduction

Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is an extremely uncommon lymphoma (incidence <1% of non-Hodgkin lymphoma) that is currently classified as a provisional entity under the Splenic B-cell Lymphoma/Leukemia Unclassifiable Category in the 2008 WHO edition, and in the recently published 2016 update of WHO Lymphoid neoplasms [1, 2]. A leukemic presentation with splenomegaly, bone marrow dissemination, and hairy cells in the peripheral blood is the ‘sine qua non’ for SDRPL, however these features are far from being specific. There is a considerable amount of morphological overlap with other lymphomas that primarily afflict the spleen and also display villous lymphocytes, such as splenic marginal zone lymphoma (SMZL), hairy-cell leukemia (HCL) and, rarely, the hairy-cell leukemia-variant (HCL-V) [3-5]. Although these similarities may pose difficulties in diagnosis, recent literature has shown convincing differences in histological, immunophenotypical, molecular, and clinical characteristics of this rare lymphoma [5-7]. Characteristic spleen histology, together with a combination of immunohistochemistry (IHC) and immunophenotyping, are essential for diagnosis. Although studies show SDRPL to be an indolent malignancy, differentiation is crucial for devising ther-

Fig. 2. Bone marrow trephine biopsy. (A-C) There is an interstitial and sinusoidal infiltrate due to a small lymphoid population (H&E, magnification ×100, ×400 and ×400). (D) Immunostaining for CD20 highlights the intrasinusoidal infiltrate (×40 magnification).

Fig. 3. Splenectomy specimen shows diffusely enlarged spleen with a beefy red homogenous cut surface and wedge-shaped subcapsular infarcts.
apeutic strategies for the patient [3, 5, 8]. SDRPL is an unfamiliar entity and we present a rare case report of a 45-year-old male who was clinically diagnosed with a splenic lymphoma.

Case Presentation

A 45-year-old male presented with abdominal swelling and generalized weakness. Co-morbidities included diabetes mellitus and alcoholic chronic liver disease. An abdominal ultrasonogram showed massive splenomegaly and mild hepatomegaly without any significant intra-abdominal lymphadenopathy. Routine blood investigations showed a total leukocyte count (TLC) count of 300×10^3/L, and a subsequent peripheral smear examination showed atypical lymphocytes with copious finger-like projections (Fig. 1). A bone marrow (BM) aspirate revealed atypical lymphoid cells (79%) with

![Fig. 4. Splenectomy specimen. (A-C) Diffuse red pulp and sinusoidal infiltration with obliteration of the white pulp. (H&E, magnification ×100, ×400 and ×400). Tumor cells are positive for CD20 (D) and DBA-44 (E). The MIB-1 proliferation index is very low (F).](image-url)
Letters to the Editor

Table 1. Summary of salient discriminating features [1, 5-11].

|                      | SMZL  | HCL    | HCL-V  | SDRPL |
|----------------------|-------|--------|--------|-------|
| **Frequency of NHL** | <2%   | 2%     | 0.4%   | 0.5%  |
| Anemia and           | Present (autoimmune) | Present | Present | Uncommon |
| thrombocytopenia      |       |        |        |       |
| **Monocytopenia**    | Absent | Present-Characteristic feature | Absent | Absent |
| **Blood smear villous lymphocytes** | Usually present with polar villi, inconspicuous nucleoli | Present with reniform nuclei, circumferential villi, inconspicuous nucleoli | Present with circumferential villi, prominent nucleoli (aka Prolymphocytic variant of HCL) | Present and similar to those reported in SMZL |
| **Spleen histology** | Micronodular pattern with white pulp replacement, marginal zone differentiation | Infiltrate in red pulp cords, atrophic white pulp, formation of RBC lakes, TRAP+ve cells | Red pulp involved, absent white pulp follicles, TRAP-ve cells | Diffuse involvement of red pulp with both cord and sinusoid infiltration, TRAP-ve cells |
| CD25                 | +     | +      | -      | -     |
| CD103                | +/-   | +      | +      | -     |
| CD123                | -     | +      | -      | -     |
| Annexin-A1           | -     | +      | +      | +     |
| DBA-44               | +/-   |       | +      | +     |
| **Genetic mutation** | NOTCH2 (-25%), VH1/2 gene | BRAFV600E (>90%) | MAP2K1 (-33%) | Unknown |
| **Associated structural abnormality** | Del 7q(-45%); trisomy 3 (less common) | Del 13q, del 7 q (uncommon) | Del 17p(TP53) (-33%) | Uncommon; Del 7q, trisomy 18, del 17p(TP53) |

Abbreviations: HCL, hairy-cell leukemia; HCL-V, hairy-cell leukemia-variant; SDRPL, small B-cell lymphoma; SMZL, splenic marginal zone lymphoma.
The leukemic presentation is typical, with massive splenomegaly and a varying magnitude of cytopenias, but B-symptoms are not encountered. Peripheral smears show the characteristic villous morphology mimicking HCL and SMZL, however, nucleoli are inconspicuous [8]. Bone marrow involvement has been seen in all reported cases to date, with an intrasinusoidal and interstitial growth pattern [4, 8, 10]. Unlike SMZL, HCL and HCL-V, which can be diagnosed on peripheral blood/BM trephine biopsy, SDRPL requires splenectomy for confirmation of the diagnosis [4]. Spleen histology shows diffuse infiltration of the red pulp due to small monotonous lymphocytes causing virtual obliteration of the white pulp [4, 8, 10], a feature in contrast to SMZL which involves only the white pulp.

SDRPL accounts for approximately 10% of lymphomas diagnosed solely on splenectomy [1, 9], necessitating the use of ancillary tests for correlation and confirmation. The immunoprofile involves characteristic tumor cells being consistently positive for CD20, DBA-44, and IgG. SDRPL is negative for CD3, CD5, CD10, CD11c, CD23, CD25, CD103, CD123, Cyclin-D1, and Annexin-A1 [3, 4, 6-8, 10].

No specific genetic mutation or chromosomal abnormality has been identified, based on the studies so far, although occasional cases have shown del 7q, del 17p(TP53) and trisomy 18 [8, 10]. Mutations seen in HCL, such as BRAF-V600E (>90% of cases) and the VHL1.2 gene, or Chromosome 7q loss as seen in SMZL, have never been observed [11].

SDRPL follows a clinically benign course with a favorable long-term survival rate. The diagnosis of SDRPL should be made based on a constellation of clinical features, peripheral smear morphology, marrow and spleen histology, immunophenotyping, and cytogenetics. Differentiation is essential as SDRPL has a good prognosis and is resistant to conventional chemotherapy that is usually effective for the treatment of HCL, HCL-V and SMZL. This is an indolent but incurable disease with a good response after splenectomy.

Conclusion

SDRPL is an extremely rare, recently recognized WHO entity with emerging distinct clinical, biological, morphological, immunohistochemical, and cytogenetic features that differ from those of other splenic lymphomas.

Acknowledgments

The authors wish to thank Dr Sukesh Nair and Dr Joy Mammen, Department of Transfusion Medicine & Immunohematology, for providing high quality images of peripheral smear.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Piris MA, Foucar KM, Mollejo M, Campo E, Falini B. Splenic lymphoma/leukemia, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008:191-3.
2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
3. Ponzoni M, Kanellis G, Poulion E, et al. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? Am J Surg Pathol 2012; 36:1609-18.
4. Behdad A, Bailey NG. Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med 2014; 138:1295-301.
5. Cesna MH, Hartung L, Tripp S, Perkins SL, Bahler DW. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol 2005; 123:132-8.
6. Dong HY, Weisberger J, Liu Z, Tugulea S. Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics. Am J Clin Pathol 2009;131:586-95.
7. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 2008;111:2253-60.
8. Kanellis G, Mollejo M, Montes-Moreno S, et al. Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica 2010;95:1122-9.
9. Gujral S, Lad P, Subramanian PG, et al. Histopathological audit of splenectomies received at a cancer hospital. Indian J Pathol Microbiol 2011;54:487-96.
10. Traverse-Glehen A, Baseggio L, Salles G, Coiffier B, Fehlan P, Berger F. Splenic diffuse red pulp small-B-cell lymphoma: toward the emergence of a new lymphoma entity. Discov Med 2012; 13:253-65.
11. Tacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15.